Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: The D:A:D study

Journal of Acquired Immune Deficiency Syndromes

Volumn 68, Issue 5, 2015, Pages 568-577

  Bruyand, Mathias ^a   Ryom, Lene ^b   Shepherd, Leah ^c   Fatkenheuer, Gerd ^d,e   Grulich, Andrew ^e   Reiss, Peter ^f,g   De Wit, Stéphane ⁱ   Darminio Monforte, Antonella ^h   Furrer, Hansjakob ^j   Pradier, Christian ^k   Lundgren, Jens ^b   Sabin, Caroline ^c  

^a INSERM   (France)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^g STICHTING HIV MONITORING   (Netherlands)

^h SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

ⁱ SAN PAOLO HOSPITAL   (Italy)

^j UNIVERSITY OF BERN   (Switzerland)

^k CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

more..

Author keywords

antiretroviral therapy; cancer; HIV; risk

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANUS CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; FEMALE; HEAD AND NECK CANCER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN CELL; INVASIVE ANAL CANCER; KAPOSI SARCOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; ADVERSE EFFECTS; FOLLOW UP; HIV INFECTIONS; INCIDENCE; MIDDLE AGED; NEOPLASMS; PROCEDURES; RISK ASSESSMENT;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RISK ASSESSMENT;

EID: 84925089152     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000523     Document Type: Article

References (39)

1. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425-432.
2. ShielsMS, Pfeiffer RM, Gail MH, et al. Cancer Burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753-762.
3. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59-67.
4. Monforte A, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS. 2008;22:2143-2153.
5. Helleberg M, Afzal S, Kronborg G, et al. Mortality Attributable to smoking among HIV-1-infected individuals: a Nationwide, populationbased cohort study. Clin Infect Dis. 2013;56:727-734.
6. Krishnan S, Schouten JT, Jacobson DL, et al. Incidence of non-AIDSdefining cancer in antiretroviral treatment-naive subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Oncology. 2011;80:42-49.
7. Chaturvedi AK, Madeleine MM, Biggar RJ, et al. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst. 2009;101:1120-1130.
8. Vallet-Pichard A, Pol S. Hepatitis viruses and human immunodeficiency virus co-infection: pathogenesis and treatment. J Hepatol. 2004;41:156-166.
9. Bruyand M, Thiebaut R, Lawson-Ayayi S, et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis. 2009;49:1109-1116.
10. Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;10:1152-1159.
11. Worm S, Bower M, Reiss P, et al. Non-AIDS defining malignancies and Immunosuppression: The D: A:D study. 19th Conference on Retroviruses and Opportunistic Infections. Washington State Convention Center, Seattle, WA, 2012.
12. Borges AH, Silverberg MJ, Wentworth D, et al. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS. 2013;27:1433-1441.
13. Androutsopoulos VP, Tsatsakis AM, Spandidos DA. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC cancer. 2009;9:187.
14. Hecht M, Harrer T, Buttner M, et al. Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system. AIDS. 2013;27:2031-2040.
15. Chow WA, Jiang C, Guan M. Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol. 2009;10:61-71.
16. Shiels MS, Cole SR, Wegner S, et al. Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters. J Acquir Immune Defic Syndr. 2008;48:485-490.
17. Crum Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009;23:41-50.
18. Chao C, Leyden WA, Xu L, et al. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS. 2012;26:2223-2231.
19. Polesel J, Clifford GM, Rickenbach M, et al. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS. 2008;22:301-306.
20. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009;27:884-890.
21. Hessol NA, Pipkin S, Schwarcz S, et al. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol. 2007;165:1143-1153.
22. Bonnet F, Balestre E, Thiebaut R, et al. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France. Clin Infect Dis. 2006;42:411-417.
23. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood. 2001;98:3406-3412.
24. Bohlius J, Schmidlin K, Costagliola D, et al. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther. 2009;14:1065-1074.
25. Piketty C, Selinger-Leneman H, Bouvier AM, et al. Incidence of HIVrelated anal Cancer remains increased despite long-term combined antiretroviral treatment: results from the French hospital database on HIV. J Clin Oncol. 2012;30:4360-4366.
26. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
27. Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15:615-625.
28. Yanik EL, Napravnik S, Cole SR, et al. Incidence and timing of Cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis. 2013;57:756-764.
29. Mbang P, Kowalkowski M, Chiao E. The effect of protease inhibitors on the incidence of HIV-associated squamous cell Carcinoma of the Anus. Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Georgia World Congress Center, Atlanta, GA.
30. Crum-Cianflone NF, Hullsiek KH, Marconi VC, et al. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS. 2010;24:535-543.
31. Palefsky JM. Antiretroviral therapy and anal cancer: the good, the bad, and the unknown. Sex Transm Dis. 2012;39:501-503.
32. Dhasmana DJ, Dheda K, Ravn P, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs. 2008;68:191-208.
33. Palefsky JM, Holly EA, Efirdc JT, et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS. 2005;19:1407-1414.
34. de Pokomandy A, Rouleau D, Ghattas G, et al. HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis. 2011;52:1174-1181.
35. Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opinion HIV AIDS. 2009;4:52-56.
36. Hernandez AL, Efird JT, Holly EA, et al. Risk factors for anal human papillomavirus infection type 16 among HIV-positive men who have sex with men in San Francisco. J Acquir Immune Defic Syndr. 2013;63:532-539.
37. Chiao EY, Giordano TP, Palefsky JM, et al. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis. 2006;43:223-233.
38. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010;202:1246-1253.
39. European AIDS Clinical Society Guidelines. version 7.0. 2013. Available at: http://www.eacsociety.org/Portals/0/Guidelines-Online-131014.pdf. Accessed July 29, 2014.